FDA accepts IND for NBI-1117567
Analysis based on 7 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026
The IND acceptance triggers a US$10 million milestone payment to Nxera, providing immediate revenue and validating its NxWave platform. Positive regulatory progress for NBI-1117567 may boost investor sentiment for both Nxera and Neurocrine, though the drug is still in early-stage development.
On 26 August 2026, Nxera Pharma announced that its partner Neurocrine Biosciences received IND Acceptance from the U.S. United States — Food and Drug Administration for a Phase 2 study of NBI-1117567, an investigational oral muscarinic M1 preferring (M1/M4) selective agonist for Alzheimer's cognition. Nxera will receive a US$10 million milestone payment from Neurocrine, expected to be recognized as revenue in Q3 FY2026. NBI-1117567 is the third compound in the muscarinic agonist portfolio to advance to Phase 2, following direclidine (NBI-1117568) in Phase 3 and NBI-1117570 in Phase 2. The collaboration agreement, signed in November 2021, grants Neurocrine development and commercialization rights to a broad portfolio of muscarinic agonists, with Nxera retaining rights for M1 agonists in Japan. Nxera is eligible for up to US$2.6 billion in milestones plus royalties.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard